Selecting the right patient for tumor therapy

Nature Medicine

Volumn 10, Issue 6, 2004, Pages 577-578

  Arteaga, Carlos L ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; GENE MUTATION; HUMAN; LUNG CANCER; PATIENT SELECTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SHORT SURVEY; TREATMENT PLANNING; TUMOR ESCAPE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; ENZYME INHIBITORS; HUMANS; LUNG NEOPLASMS; MUTATION; PATIENT SELECTION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 2942722368     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0604-577     Document Type: Short Survey

References (17)

1. Arteaga, C.L. J. Clin. Oncol. 19, 32S-40S (2001).
2. Fukuoka, M. et al. J. Clin. Oncol. 21, 2237-2246 (2003).
3. Kris, M.G. et al. JAMA 290, 2149-2158 (2003).
4. Giaccone, G. et al. J. Clin. Oncol. 22, 777-784 (2004).
5. Herbst, R.S. et al. J. Clin. Oncol. 22, 785-794 (2004).
6. Paez, J.G. et al. Science published online 29 April 2004 (doi: 10.1126/science. 1099314).
7. Lynch, T.J. et al. N. Engl. J. Med. published online 29 April 2004 (doi: 10.1056/NEJMoa040938).
8. Yarden, Y. & Sliwkowski, M.X. Nat. Rev. Mol. Cell Biol. 2, 127-137 (2001).
9. Antonyak, M.A., Moscatello, D.K. & Wong, A.J. J. Biol. Chem. 273, 2817-2822 (1998).
10. Huang, H.S. et al. J. Biol. Chem. 272, 2927-2935 (1997).
11. Prados, M. et al. Proc. Am. Soc. Clin. Oncol. 22, 99 (2003).
12. Schwartz, G. et al. Proc. Am. Soc. Clin. Oncol. 21, 24a (2002).
13. Saltz, L. et al. Proc. Am. Soc. Clin. Oncol. 21, 127a (2002).
14. Nagar, B. et al. Cancer Res. 62, 4236-4243 (2002).
15. Huron, D.R. et al. Clin. Cancer. Res. 9, 1267-1273 (2003).
16. Bardelli, A. et al. Science 300, 949 (2003).
17. Samuels, Y. et al. Science 304, 554 (2004).